mTOR Pathway and Is Counteracted by the PI3K Inhibitor MEN1611

Overview of attention for article published in Frontiers in oncology, July 2021

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

twitter: 2 X users

Readers on

mendeley: 10 Mendeley

Summary X

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 6,574 followers.

New research: Tumor Growth in the High Frequency Medulloblastoma Mouse Model Ptch1+/−/Tis21KO Has a Specific Activation Signature of the PI3K/AKT/mTOR Pathway and Is Counteracted by the PI3K Inhibitor MEN1611: We have previously generated a… https://t.co/V

30 Jul 2021

Reply Repost Favourite

Tumor growth in the high frequency medulloblastoma mouse model Ptch1+/−/Tis21KO has a specific activation signature of the PI3K/AKT/mTOR pathway and is counteracted by the PI3K inhibitor MEN1611 https://t.co/NgAabnDeNv

12 Jul 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.